血清淀粉样蛋白A在新生儿败血症、坏死性小肠结肠炎早期诊断中的价值

新生儿早/晚发型败血症(EOS/LOS)、坏死性小肠结肠炎(NEC)是新生儿期常见疾病，严重病例预后不良。因早期临床表现不特异、诊断较困难，现非特异性实验室检查(C反应蛋白，降钙素原等)尚存缺点，可能导致漏诊误诊。血清淀粉样蛋白A(SAA)是一种新型急性期反应物，其在EOS/LOS、NEC早期即明显升高、持续时间久，与疾病严重程度相关、且能反映治疗效果，可作为这两种疾病诊治的生物标记物。本文就SAA及其在EOS/LOS、NEC早期诊断中的价值进行综述，为该类疾病诊治提供新的参考。

The value of serum amyloid protein A in the early diagnosis of neonatal sepsis and necrotizing enterocolitis

Early/late onset sepsis (EOS/LOS) and necrotizing enterocolitis (NEC) are common diseases during the neonatal period, with poor prognosis in severe cases. The early clinical manifestations are not specific, the diagnosis is difficult, currently-used non-specific laboratory tests (C-reactive protein, procalcitonin, etc.) have disadvantages, which may lead to missed diagnosis or misdiagnosis. Serum amyloid A (SAA) is a novel acute phase reactant that increases significantly in the early stage of EOS/LOS and NEC, and lasts for a long time, it is related to the severity of the disease and can reflect the therapeutic effect, thus it can be used as a biomarker for diagnosis and treatment of these two diseases. This paper reviews SAA and its value in the early diagnosis of EOS/LOS and NEC, providing new references for the diagnosis and treatment of such diseases.